Abstract

Microbial Drug ResistanceVol. 1, No. 1 Pneumococcal Conjugate Vaccines: Review and UpdateDAVID L. KLEINDAVID L. KLEINSearch for more papers by this authorPublished Online:29 Jan 2009https://doi.org/10.1089/mdr.1995.1.49AboutSectionsPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited ByPolyester as Antigen Carrier toward Particulate Vaccines24 May 2019 | Biomacromolecules, Vol. 20, No. 9Decrease in Hospitalizations for Pneumonia in Children under Five Years of Age in an Indian Reservation in Panama after the Introduction of the Heptavalent Pneumococcal Conjugate Vaccine (PCV7)International Journal of Pediatrics, Vol. 2013The viridans group streptococciReviews in Medical Microbiology, Vol. 21, No. 4Glycoconjugate vaccines and immune interference: A reviewVaccine, Vol. 28, No. 34Automation of the Anthrone Assay for Carbohydrate Concentration Determinations2 February 2010 | Analytical Chemistry, Vol. 82, No. 5PNEUMOCOCCAL INFECTIONSComparison of secular trends in pneumococcal serotypes causing invasive disease in Denver, Colorado (1971–2004) and serotype coverage by marketed pneumococcal vaccinesClinical Microbiology and Infection, Vol. 12, No. 11Serotypes of carriage and invasive isolates of Streptococcus pneumoniae in Brazilian children in the era of pneumococcal vaccinesClinical Microbiology and Infection, Vol. 12, No. 1Identification of Invasive Serotype 1 Pneumococcal Isolates That Express Nonhemolytic PneumolysinJournal of Clinical Microbiology, Vol. 44, No. 1Determination of saccharide content in pneumococcal polysaccharides and conjugate vaccines by GC-MSDAnalytical Biochemistry, Vol. 347, No. 2Heptavalent pneumococcal conjugate vaccine: current and future impact9 January 2014 | Expert Review of Vaccines, Vol. 2, No. 57. Vaccine4 December 2016 | Annals of Otology, Rhinology & Laryngology, Vol. 111, No. 3_supplThe Prevention of Pneumococcal Disease in ChildrenNew England Journal of Medicine, Vol. 345, No. 16Minimizing Potential Resistance: A Population Dynamics ViewClinical Infectious Diseases, Vol. 33, No. s3The Prevention of Pneumococcal Disease by Vaccines: Promises and ChallengesInfectious Disease Clinics of North America, Vol. 15, No. 1Role of communicable disease control measures in affecting the spread of resistant pneumococci: the Swedish modelClinical Microbiology and Infection, Vol. 5Carriage of resistant pneumococci by children in southern Israel and impact of conjugate vaccines on carriageClinical Microbiology and Infection, Vol. 5Treatment options for resistant pneumococcal infectionsClinical Microbiology and Infection, Vol. 5Development and testing of Streptococcus pneumoniae conjugate vaccinesClinical Microbiology and Infection, Vol. 5The epidemiology of pneumococcal infection in children in the developing worldPhilosophical Transactions of the Royal Society of London. Series B: Biological Sciences, Vol. 354, No. 1384The burden of pneumococcal disease: the role of conjugate vaccinesVaccine, Vol. 17, No. 13-14Vaccines Against Streptococcus pneumoniaeSerotyping and antibiotic resistance of Streptococcus pneumoniae isolated from pediatric infections in central GreeceClinical Microbiology and Infection, Vol. 4, No. 12Antimicrobial susceptibility of Streptococcus pneumoniae from children attending day-care lefts in a central Italian cityClinical Microbiology and Infection, Vol. 4, No. 11Emergence of Penicillin Resistance in Recurrent Pneumococcal Endocarditis in an HIV-Infected Patient CHRISTOPHER GONZAGA and LISA L. DEVER29 January 2009 | Microbial Drug Resistance, Vol. 4, No. 1Limiting the Spread of Penicillin-Resistant Streptococcus pneumoniae: Experiences from the South Swedish Pneumococcal Intervention Project KARL EKDAHL, HANS BERTIL HANSSON, SIGVARD MÖLSTAD, MARGARETA SÓDERSTRÖM, MATS WALDER, and KRISTINA PERSSON29 January 2009 | Microbial Drug Resistance, Vol. 4, No. 2Vaccination Against Middle-ear Bacterial and Viral PathogensAnnals of the New York Academy of Sciences, Vol. 830, No. 1 Immunologic DSafety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigensThe Pediatric Infectious Disease Journal, Vol. 16, No. 11Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoidThe Pediatric Infectious Disease Journal, Vol. 16, No. 11Safety and Immunogenicity of Three Doses of a Five-Valent Pneumococcal Conjugate Vaccine in Children Younger Than Two Years With and Without Human Immunodeficiency Virus Infection1 April 1997 | Pediatrics, Vol. 99, No. 4Effect of Antimicrobial Use and Other Risk Factors on Antimicrobial Resistance in Pneumococci KARL G. KRISTINSSON29 January 2009 | Microbial Drug Resistance, Vol. 3, No. 2Epidemiology of Pneumococcal Serotypes and Conjugate Vaccine Formulations JAY C. BUTLER29 January 2009 | Microbial Drug Resistance, Vol. 3, No. 2Combination VaccinesAntimicrobial Resistance of Invasive Streptococcus pneumoniae in Slovenia, 1993-19958 July 2009 | Scandinavian Journal of Infectious Diseases, Vol. 29, No. 3CURRENT PERSPECTIVES ON MULTIDRUG-RESISTANT BACTERIAInfectious Disease Clinics of North America, Vol. 10, No. 4Infections Due to Drug-Resistant Pneumococci, Enterococci, and Mycobacterium tuberculosisPediatric Annals, Vol. 25, No. 9Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected childrenThe Pediatric Infectious Disease Journal, Vol. 15, No. 3 Volume 1Issue 1Jan 1995 To cite this article:DAVID L. KLEIN.Pneumococcal Conjugate Vaccines: Review and Update.Microbial Drug Resistance.Jan 1995.49-58.http://doi.org/10.1089/mdr.1995.1.49Published in Volume: 1 Issue 1: January 29, 2009PDF download

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call